findmyKOL
Clinical trialNCT02283177CompletedPhase 2Interventional

A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

SponsorArog Pharmaceuticals, Inc.Enrollment44Newly Diagnosed AML With FLT3 Activating Mutations
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • City of Hope Medical Center

    Duarte, California, United States

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

  • Weill Cornell Medical College

    New York, New York, United States

  • Cleveland Clinic

    Cleveland, Ohio, United States

  • University of Texas Southwestern Medical Center

    Dallas, Texas, United States

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jan 2015
Primary completion
31 Dec 2019
Completion
31 Dec 2019
Last update posted
2 Feb 2024
Registered enrollment
44
Registry id
NCT02283177

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.